Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO) [1] Group 1: Strategic Cooperation - The agreement establishes a strategic partnership between Pro Pharmaceutical and Xi'an New Tong, focusing on long-term collaboration in CDMO projects [1] - This collaboration is expected to enhance Pro Pharmaceutical's CDMO business competitiveness and facilitate its expansion in this sector [1] Group 2: Xi'an New Tong's IPO - Xi'an New Tong is currently preparing for an IPO on the Sci-Tech Innovation Board, with its application accepted on December 29, 2025, aiming to raise 900 million yuan [1]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as custom manufacturing projects [2] Group 1 - The agreement does not involve substantial transactions and will not have a significant impact on the company's operating performance for the current year [2] - The future impact on the company's operating performance will depend on subsequent specific project agreements and their implementation [2]

Core Viewpoint - The company has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development as well as outsourced custom manufacturing projects [1] Group 1: Agreement Details - The agreement is a framework agreement and does not involve substantial transactions or constitute a major asset restructuring [1] - The collaboration is expected to benefit the company's CDMO (Contract Development and Manufacturing Organization) business expansion and enhance its competitive edge [1] Group 2: Financial Impact - The agreement is not expected to have a significant impact on the company's operating performance for the current fiscal year [1] - Future performance implications will depend on subsequent specific project agreements and their implementation [1]